'MyBioPharmaSpace'

Medicines Australia says a new report has revealed the significant benefits of investing in adult vaccination programs.

Medicines Australia CEO Liz de Somer said, "The Productivity Commission research recognises that advances in cancer treatments have been one of the major drivers of productivity growth, and this is consistent with productivity studies from overseas."

The claims surrounding health system carbon emissions are being used to push significant changes in funding decisions and care delivery but rely on unpublished data, woolly assumptions and implausible assertions.

Noxopharm CEO Dr Gisela Mautner said, “We are very grateful to the Tour de Cure team for funding this promising research. With this grant, our preclinical drug candidate is recognised as having potential that warrants further investigation and development."

Novartis has announced that it will propose former CEO of Bristol Myers Squibb, Dr Giovanni Caforio, as the new chair of its board of directors.

AstraZeneca has released a new episode of its recently launched TrailblAZers video podcast featuring New Zealand MP Todd Stephenson.

The association's newly-appointed leader said, “I’m honoured to join AusBiotech as its incoming CEO, and to help the team build on the outstanding work delivered for members every day.”

An NDIS participant with a chronic condition can enjoy a taxpayer-supported cruise with their support team. Does it make sense that, at the same time, they could be denied funded access to medicine or other health technology that could significantly improve their health and quality of life? Where is the equity and opportunity cost in that?

RCA CEO Christine Cockburn said the appointments have been made at a good time as the organisation implements its new three-year strategic plan, which is focused on strengthening advocacy and outcomes for the rare cancer community.

Bristol Myers Squibb has joined Brandon Capital, a leading Australian life sciences private equity firm, in supporting Pathios Therapeutics' Series B financing.

Diabetes patients in New Zealand are rebelling against the plan to forcibly switch their use of insulin pumps following a Pharmac tender.

Noxopharm CEO Dr Gisela Mautner added, “We are very grateful to the Tour de Cure team for funding this promising research. With this grant, our preclinical drug candidate is recognised as having potential that warrants further investigation and development."